期刊
CLINICAL LUNG CANCER
卷 22, 期 5, 页码 E738-E744出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2021.01.014
关键词
Immunotherapy; Interstitial lung disease; Idiopathic pulmonary fibrosis; X-Ray Computed tomography; Carcinomas
类别
资金
- Queen's University School of Medicine
- NIH [T32HL116275, T32-AR-007258, K23HL150331]
- NIH (NCI) [U01CA209414]
- Francis Family Foundation
- Scleroderma Foundation
This study found that patients with ILD receiving PD-1 inhibitors more frequently died from cancer-related causes than from ILD. Further research is needed to determine the safety of ICIs in patients with ILD and if ILD subtype may help to refine ICI-associated risks.
This study explores clinical and radiologic outcomes of PD-1 inhibitor use in patients with ILD, who have traditionally been excluded from PD-1 inhibitor safety and efficacy trials. We included 41 patients with radiographic evidence of ILD in the study. Our findings suggest that PD-1 inhibitors for oncologic indications should not be uniformly withheld in patients with underlying ILD. Background: Immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) inhibitors, are used to treat multiple cancers. Limited data exist as to the use of ICIs in patients with coexistent interstitial lung disease (ILD). We conducted a retrospective case series to assess clinical and radiologic outcomes of patients with ILD treated with PD-1 inhibitors. Methods: Eligible patients were 18 years of age or older, treated with pembrolizumab or nivolumab for oncologic indications, and had evidence of ILD on chest computed tomography scan not attributable to radiotherapy before initiation of ICI therapy. Outcomes of interest included mortality, hospitalizations for respiratory-related causes, development of pneumonitis, and radiologic change in ILD over a 1-year follow-up period. Results: We included 41 patients in the analysis. At 1 year, 17 patients (41.5%) were alive, 23 had died (56.1%), and 1 (2.4%) was lost to follow-up. Of 23 deaths, 16 (69.6%) were due to cancer, 4 (17.4%) to causes excluding cancer and ILD, and 3 (13.0%) to hypoxemic respiratory failure from ILD- or ICI-induced pneumonitis. Three patients (7.3%) required hospitalization owing to ILD, including drug-induced pneumonitis, and 3 (7.3%) developed pneumonitis attributable to anti-PD-1 therapy. On follow-up computed tomography scans, 32 patients (78.0%) had stable or improved ILD and 9 (22.0%) had progression. Conclusion: Patients with ILD receiving PD-1 inhibitors more frequently died of cancer-related causes than from ILD. Further research is needed to determine the safety of ICIs in patients with ILD and if ILD subtype may help to refine ICI-associated risks. (C) 2021 The Author(s). Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据